INTRAVITREAL XXXX IMPLANT FOR RADIATION MACULOPATHY SECONDARY TO PLAQUE BRACHYTHERAPY IN CHOROIDAL MELANOMA.

@entity1103 @entity619 @entity2184 @entity1020 @entity320
PURPOSE: To evaluate the efficacy of intravitreal @entity619 implant 0.7 mg (Ozurdex) in radiation @entity1020 secondary to plaque brachytherapy in @entity320 . METHODS: Twelve eyes diagnosed of radiation @entity1020 secondary to plaque brachytherapy and treated with intravitreal @entity619 implant were included. Visual acuity, foveal thickness using spectral domain optical coherence tomography, and grade of @entity1103 , using Horgan classification, were evaluated. RESULTS: Mean age was 65.5    28 years (range, 40-82 years). Mean follow-up was 8.2    7.8 months (range, 2-28 months). Mean visual acuity before treatment was, in logarithm of the minimum angle of resolution scale, 1    0.58 (range, 0.4-2) and mean final visual acuity 0.8    0.58 (range, 0.2-2), showing a nonsignificant trend to improvement (P = 0.091; Wilcoxon's test). Foveal thickness before treatment was 416    263  m (range, 222-725  m) and final foveal thickness 254    170  m (range, 145-750), showing a significant decrease (P = 0.016; Wilcoxon's test). Referring to Horgan classification, a significant reduction in grades before and after treatment was demonstrated (P = 0.007; Wilcoxon's test). CONCLUSION: Ozurdex is a useful treatment for radiation @entity1020 associated to plaque brachytherapy for @entity2184 , with a significant decrease in foveal thickness and a significant improvement in Horgan classification. This anatomical improvement was correlated with a moderate improvement in visual acuity.
